UGNEQ

 
Common Stock SEC Reporting - Delinquent
Pink No Information
Contact Info
  • 81 Fulton Street
  • Boonton, NJ 07005

Business Description


Update Company Profile
 
Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report Mar 31, 2013 10-Q
CIK 0000352747
Fiscal Year End 12/31
OTC Marketplace Pink No Information
Profile Data
SIC - Industry Classification 2833 - Medicinal and botanicals
Incorporated In: DE, USA
Year of Inc. Not Available
Employees Not Available
Company Officers/Contacts
William Steinhauer VP, Fin.
Company Directors
Not Available
Service Providers
Accounting/Auditing Firm
Grant Thornton
226 Causeway Street
Boston, MA, 02114
United States
 
Securities Counsel

Not Available
Investor Relations Firm

Not Available
Company History
  • Note = On July 2, 2013, Unigene Laboratories, Inc. filed a voluntary petition for relief under Chapter 7 of the United States Bankruptcy Code in the United States Bankruptcy Court of the District of New Jersey.
UGNEQ Security Details
Share Structure
Market Value1 $19,196 a/o Oct 23, 2017
Authorized Shares Not Available
Outstanding Shares 95,978,952 a/o Apr 30, 2013
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float Not Available
Par Value 0.01
Transfer Agent(s)
Computershare
Shareholders
Shareholders of Record 462 a/o Mar 15, 2013
Short Selling Data
Short Interest 0 (-100%)
Feb 15, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security